FavId, a patient-specific idiotypic vaccine for non-Hodgkin's lymphoma

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 3, 2007, Pages 291-298

  Reinis, M ^a  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FAVID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN IDIOTYPE; KEYHOLE LIMPET HEMOCYANIN; PLACEBO; PREDNISONE; RITUXIMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINE; VINCRISTINE; CANCER VACCINE; HEMOCYANIN; KEYHOLE-LIMPET HEMOCYANIN;

ANTIGEN PRESENTATION; BACULOVIRUS EXPRESSION SYSTEM; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; HEADACHE; HUMAN; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; LIVER ABSCESS; META ANALYSIS; MONOTHERAPY; MYALGIA; NONHODGKIN LYMPHOMA; NONHUMAN; PAIN; PRURITUS; REVIEW; SKIN INDURATION; STRUCTURE ACTIVITY RELATION; SYNCOPE; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; VITREOUS HEMORRHAGE; ANIMAL; ARTICLE; CONTROLLED CLINICAL TRIAL; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; CANCER VACCINES; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DRUG EVALUATION, PRECLINICAL; HEMOCYANIN; HUMANS; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY; LYMPHOMA, NON-HODGKIN; RANDOMIZED CONTROLLED TRIALS;

EID: 34250614413     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Clinical trials: Phase III NHL. Genitope Corp COMPANY WORLD WIDE WEB SITE 2000 December 19
2. Favrille completes $16.9 million financing. Favrille Inc PRESS RELEASE 2002 June 11
3. Clinical trials: Information for patients and healthcare professionals. Favrille Inc COMPANY WORLD WIDE WEB SITE 2002 June 12
4. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: Clinical and immune responses in 35 patients. Timmerman JM, Czerwinski DK, Davis TA, Hsu FJ, Benike C, Hao ZM, Taidi B, Rajapaksa R, Caspar CB, Okada CY, van Beckhoven A et al BLOOD 2002 99 5 1517-1526
5. Clinical results of the ID-KLH vaccination with local GM-CSF in patients with follicular lymphomas (published in Nature Med 1999; 5: 1171-1177) summary of the lecture by L W Kwak. Schumacher K J CANCER RES CLIN ONCOL 2001 127 2 R10- 2 R13
6. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. Timmerman JM, Levy R J IMMUNOL 2000 164 9 4797-4803
7. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte-macrophage colony-stimulating factor primes mice for a protective T-cell response. Kwak LW, Young HA, Pennington RW, Weeks SD PROC NATL ACAD SCI USA 1996 93 20 10972-10977
8. Efficacy of idiotypic vaccination in mice bearing B-cell lymphoma. Khan NA IN VIVO 1989 3 2 117-119
9. Idiotype vaccination in human myeloma: Generation of tumor-specific immune responses after high-dose chemotherapy. Massaia M, Borrione P, Battaglio S, Mariani S, Beggiato E, Napoli P, Voena C, Bianchi A, Coscia M, Besostri B, Peola S et al BLOOD 1999 94 2 673-683
10. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Timmerman JM, Singh G, Hermanson G, Hobart P, Czerwinski DK, Taidi B, Rajapaksa R, Caspar CB, Van Beckhoven A, Levy R CANCER RES 2002 62 20 5845-5852
11. Single agent activity of FavId [Id-KLH vaccine] for indolent NHL. Redfern C, Guthrie TH, Adler M, Holman P, Smith MR, Levy R, Janakiraman N, Leonard JP, Rosenfelt F, Wiernik PH, Just R et al BLOOD 2003 102 11 Abs 3341
12. Favid [Id-KLH vaccine] following rituximab for patients with indolent NHL. Gold D, Redfern C, Wiernik PH, Guthrie TH, Rosenfelt F, Koc ON, Winter JN, Holman P, Kaplan L, Hainsworth J, Castillo RA et al BLOOD 2003 102 11 Abs 3347
13. Antibody therapy for non-Hodgkin's lymphoma. Ansell SM CURR OPIN MOL THER 2004 6 2 175-181
14. Successful anti-Id T-cell responses to Id-KLH immunotherapy in B-cell depleted patients with follicular lymphoma (FL) may prolong TTP after rituximab: Phase II trial of FavId. Koc ON, Redfern C, Wiernik P, Rosenfelt F, Winter J, Guthrie T, Kaplan L, Holman P, Densmore J, Hainsworth J PROC AM SOC CLIN ONCOL 2004 23 Abs 2520
15. Favrille Inc initiates phase III clinical trial. Favrille Inc PRESS RELEASE 2004 September 22
16. Id/KLH vaccine (FavId) following treatment with rituximab: An analysis of response rate improvement (RRI) and time-to-progression (TTP) in follicular lymphoma (FL). Koc ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Guthrie TH, Kaplan L, Holman P, Densmore J, Hainsworth J, Lin T et al BLOOD 2004 104 11 Abs 587
17. A phase 2 trial to evaluate the efficacy of recombinant idiotype vaccine with abbreviated course of granulocyte-macrophage colony-stimulating factor adjuvant in follicular non-Hodgkin's lymphoma. Vose J, Bierman P, Hollingsworth M, Ingolia D, Denney D, Kunkel L BLOOD 2002 100 11 Abs 1397
18. Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies. Leitch HA, Connors JM CURR OPIN INVESTIG DRUGS 2005 6 6 597-604
19. Favrille begins European phase II trial of FavId against NHL. Favrille Inc PRESS RELEASE 2005 June 06
20. American Society of Hematology - 47th Annual Meeting and Exposition (Part I) - Overnight Report, Corporate Friday Symposia, Atlanta, GA, USA, 10-13 December 2005. Murch L IDDB MEETING REPORT 2005 December 10-13
21. Long-term follow-up of patients treated in a phase 2 trial with MyVax personalized immunotherapy (recombinant Id-KLH with GM-CSF) after chemotherapy as initial treatment for follicular non-Hodgkin's lymphoma. Timmerman JM, Vose J, Levy R, Mayo M, Denney D BLOOD 2005 106 11 Abs 2438
22. American Society of Hematology - 47th Annual Meeting and Exposition (Part V) - Overnight Report, Atlanta, GA, USA, 10-13 December 2005. Murch L IDDB MEETING REPORT 2005 December 10-13
23. Extended follow-up and analysis with central radiological review of patients receiving Favid (Id/KLH) vaccine following rituximab. Koc O, Redfern C, Wiernik P, Rosenfelt F, Winter J, Guthrie T, Kaplan L, Holman P, Densmore J, Hainsworth J, Lin T et al BLOOD 2005 106 11 Abs 772
24. Favrille receives US Fast Track status for NHL vaccine. Favrille Inc PRESS RELEASE 2006 January 12
25. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. Redfern CH, Guthrie TH, Bessudo A, Densmore JJ, Holman PR, Janakiraman N, Leonard JP, Levy RL, Just RG, Smith MR, Rosenfelt FP et al J CLIN ONCOL 2006 24 19 3107-3112
26. Baculovirus Technology - CHI's Inaugural Conference, Boston, MA, USA, 25-26 September 2006. McPherson C IDDB MEETING REPORT 2006 September 25-26
27. Cancer Immunotherapy 2006, New York, NY, USA. Riedlinger G, Cui Z IDDB MEETING REPORT 2006 October 04-06
28. Favrille's FavId fails to meet secondary endpoint in phase III B-cell NHL trial. Favrille Inc PRESS RELEASE 2006 November 13
29. Early and robust immune responses to idiotype (Id) vaccination occur in mantle cell lymphoma (MCL) and indolent lymphoma (IL) patients following autologous stem cell transplantation (ASCT). Holman P, Medina B, Corringham S, Bashey A, Carrier E, Mu X, Gold D, Ball E BLOOD 2003 102 11 Pt 1 899a
30. Immune response to idiotype vaccination following high dose chemotherapy + autologous stem cell transplant in indolent and mantle cell lymphoma. Holman P, Bashey A, Carrier E, Corringham S, Davis B, Oblon DJ, Chen J, Gold D, Mu X, Ball ED BLOOD 2002 100 11 Pt 2 315b
31. Phase III trial of active immunotherapy (FavId, Id/KLH) following rituximab induction therapy: Clinical responses in patients (pts) with follicular non-Hodgkin's lymphoma (fNHL). Freedman AS, Hamlin PA, Neelapu S, Nichols C, Robertson M, Bergier G, Winter JN, Polikoff J, Lin T, Pohlman B, Esquibel V et al BLOOD 2006 108 11 Abs 2756
32. Favrille's FavId leads to durable remission in NHL patients. Favrille Inc PRESS RELEASE 2007 February 12
33. Favrille announces agreement with Berlex, Inc. regarding use of FavId in combination with Leukine (sargramostim) in B-cell non-Hodgkin's lymphoma. PRESS RELEASE 2007 February 14
34. Cancer immunotherapy: Moving beyond current vaccines. Rosenberg SA, Yang JC, Restifo NP NAT MED 2004 10 9 909-915
35. Cancer statistics, 2007. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ CA CANCER J CLIN 2007 57 1 43-66
36. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V et al J CLIN ONCOL 1998 16 8 2825-2833
37. Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma. Ruffini PA, Di Nicola M, Carlo-Stella C, Siena S, Gianni AM CURR GENE THER 2005 5 5 511-521
38. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, Watson TM, Reynolds CW, Gause BL, Duffey PL, Jaffe ES et al NAT MED 1999 5 10 1171-1177
39. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R N ENGL J MED 1992 327 17 1209-1215
40. Myeloma proteins as tumor-specific transplantation antigens. Lynch RG, Graff RJ, Sirisinha S, Simms ES, Eisen HN PROC NATL ACAD SCI USA 1972 69 6 1540-1544
41. Idiotypic vaccination as a treatment for a B cell lymphoma. George AJ, Folkard SG, Hamblin TJ, Stevenson FK J IMMUNOL 1988 141 6 2168-2174
42. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins. Sirisinha S, Eisen HN PROC NATL ACAD SCI USA 1971 68 12 3130-3135
43. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - long-term results of a clinical trial. Hsu FJ, Caspar CB, Czerwinski D, Kwak LW, Liles TM, Syrengelas A, Taidi-Laskowski B, Levy R BLOOD 1997 89 9 3129-3135
44. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: Initial studies in a murine model. Kwak LW, Campbell M, Levy R CANCER DETECT PREV 1991 15 4 323-325
45. BiovaxID: A personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma. Lee ST, Jiang YF, Park KU, Woo AF, Neelapu SS EXPERT OPIN BIOL THER 2007 7 1 113-122
46. Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma. Oki Y, McLaughlin P, Fayad LE, Pro B, Mansfield PF, Clayman GL, Medeiros LJ, Kwak LW, Srivastava PK, Younes A CANCER 2007 109 1 77-83
47. Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Weng WK, Czerwinski D, Levy R BLOOD 2007 109 3 951-953
48. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. Weng WK, Czerwinski D, Timmerman J, Hsu FJ, Levy R J CLIN ONCOL 2004 22 23 4717-4724
49. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: A focus on FavId. Hurvitz SA, Timmerman JM EXPERT OPIN BIOL THER 2005 5 6 841-852
50. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Bendandi M, Rodriguez-Calvillo M, Inoges S, Lopez-Diaz de Cerio A, Perez-Simon JA, Rodriguez-Caballero A, Garcia-Montero A, Almeida J, Zabalegui N, Giraldo P, San Miguel J et al LEUK LYMPHOMA 2006 47 1 29-37
51. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations. Caspar CB, Levy S, Levy R BLOOD 1997 90 9 3699-3706
52. Idiotypic determinants on the surface immunoglobulin of neoplastic lymphocytes: A therapeutic target. Stevenson GT, Elliott EV, Stevenson FK FED PROC 1977 36 9 2268-2271
53. Use of rituximab, the new FDA-approved antibody. Leget GA, Czuczman MS CURR OPIN ONCOL 1998 10 6 548-551
54. Follicular lymphoma: Time for a re-think? Gandhi MK, Marcus RE BLOOD REV 2005 19 3 165-178
55. Idiotypic vaccination in B-cell malignancies. Bianchi A, Massaia M MOL MED TODAY 1997 3 10 435-441
56. Update on epidemiology and therapeutics for non-Hodgkin's lymphoma. Vose JM, Chiu BC, Cheson BD, Dancey J, Wright J HEMATOLOGY AM SOC HEMATOL EDUCATION PROGRAM 2002 241-262
57. Active immunotherapy with FavId (Id/KLH) following rituximab induction: Long-term follow-up of response rate improvement (RRI) and disease progression in follicular lymphoma patients (pts). Koc ON, Redfern C, Wiernik PH, Rosenfelt F, Winter JN, Guthrie TH, Kaplan L, Holman P, Densmore J, Hainsworth J, Lin TS et al BLOOD 2006 108 11 Abs 691
58. Id/KLH active immunotherapy (FavId) following high dose therapy (HDT) and autologous stem cell transplantation (ASCT) for non-Hodgkins lymphoma (NHL). Holman PP, de Magalhaes-Silverman M, Corringham S, Castro JE, Carrier E, Lane T, Gold D, Ball E ANN MEET AM SOC BLOOD MARROW TRANSPLANT 2007 9 Abs 145
59. Baculovirus vectors for gene therapy. Hu YC ADV VIRUS RES 2006 68 287-320
60. Idiotype vaccination in follicular lymphoma: Knocking on the doorway to cure. Longo DL J NATL CANCER INST 2006 98 18 1263-1265
61. NCT00324831: GM-CSF with or without vaccine therapy after combination chemotherapy and rituximab as first-line therapy in treating patients with stage II, stage III, or stage IV diffuse large B-cell lymphoma. National Cancer Institute CLINICALTRIALS.GOV 2007 April 09
62. NCT00104819: Vaccine therapy and GM-CSF in treating patients with progressive non-Hodgkin's lymphoma. National Cancer Institute CLINICALTRIALS.GOV 2007 March 20